Rapamycin Nanoparticles Increase the Therapeutic Window of Engineered Interleukin-2 and Drive Expansion of Antigen-Specific Regulatory T Cells for Protection against Autoimmune Disease

Researchers demonstrated that the combination of biodegradable nanoparticles encapsulating rapamycin and an engineered Treg-selective IL-2 variant increased the number and durability of total Tregs, as well as induced a profound synergistic increase in antigen-specific Tregs when combined with a target antigen.